Global Paclitaxel Market Growth 2023-2029
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
LPI (LP Information)' newest research report, the “Paclitaxel Industry Forecast” looks at past sales and reviews total world Paclitaxel sales in 2022, providing a comprehensive analysis by region and market sector of projected Paclitaxel sales for 2023 through 2029. With Paclitaxel sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Paclitaxel industry.
This Insight Report provides a comprehensive analysis of the global Paclitaxel landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Paclitaxel portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Paclitaxel market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Paclitaxel and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Paclitaxel.
The global Paclitaxel market size is projected to grow from US$ 115 million in 2022 to US$ 203.7 million in 2029; it is expected to grow at a CAGR of 203.7 from 2023 to 2029.
North America and China are the largest producer of Paclitaxel, with a market share about 35% separately. Phyton, ScinoPharm, Huiang biopharma, Southpharma and Novasep are the top 5 manufacturers of industry, and they had more than 60% combined market share.
This report presents a comprehensive overview, market shares, and growth opportunities of Paclitaxel market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
Segmentation by application
Ovarian Cancer
Cervical Cancer
Breast Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Paclitaxel market?
What factors are driving Paclitaxel market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paclitaxel market opportunities vary by end market size?
How does Paclitaxel break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook